Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3871801 Pharmacokinetics and Drug Interaction Study
NCT05602675Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ocadusertib in rheumatoid arthritis (RA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Methotrexate at 48 hours, Area Under the Plasma Concentration Versus Time Curve of Methotrexate at 48 hours and 8 more. Started Nov 2022; status: completed.
02
Drugs
ocadusertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05602675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602675.